重组人干扰素α2b联合复方异丙托溴铵在支气管哮喘合并病毒性肺炎患儿治疗中的应用OA

Objective:To analyze the clinical efficacy of recombinant human interferon α2b combined with compound ipratropium bromide in the treatment of children with bronchial asthma complicated with viral pneumonia.Methods:A total of 140 children with bronchial asthma and viral pneumonia treated in a hospital from May 2021 to May 2023 were selected and divided into the control group and observation group by random number table method,with 70 patients in each group.Both groups were treated with conventional therapy,the control group was additionally treated with compound ipratropium bromide,and the observation group was additionally given recombinant human interferon α2b.The treatment continued for 7 days.After treatment,the total response rate and the time to disappearance of symptoms such as fever,pulmonary shadow,cough,and pulmonary rale were compared between the two groups,and the occurrence of adverse reactions during the treatment was recorded.Results:After 7 days of treatment,the response rate was higher in the observation group(92.86%)than that in the control group(72.86%,P<0.05).The time to fever clearance,disappearance of pulmonary shadow,improvement of cough and disappearance of lung rale in the observation group was shorter as compared with the control group(P<0.05).No adverse reactions occurred in either group during the treatment.Conclusion:Favorable overall efficacy was demonstrated with recombinant human interferon α2b combined with compound ipratropium bromide in the treatment of children with bronchial asthma complicated with viral pneumonia as it was conducive to rapid relief of main symptoms without additional risk of adverse reactions.